Whole-body 18F-FDG PET/CT and MicroPET/CT Imaging

Whole-body 18F-FDG PET/CT and MicroPET/CT Imaging

18F-FDG-PET/CT technology combines anatomical image CT and functional metabolic image PET, which can detect the initial state of the tumor before the clinical symptoms or anatomical structure changes of the tumor, and can be used in clinical early diagnosis. Whole-body 18F-FDG-PET/CT in tumor-bearing mice can detect glucose uptake in specific tissues in real-time, which is of great significance for the study of cancer tissue glucose metabolism. Micro-PET is a small and high-resolution positron emission tomography imaging technology. It has the advantages of fast imaging speed, high sensitivity, and small toxic and side effects. It can be applied to in vivo imaging of tumor-bearing mice to study the metabolic status of tumor-bearing mice. CD BioGlyco provides whole-body 18F-FDG PET/CT and micro-PET/CT imaging assays of tumor-bearing mice.

Detection Principle

The radiotracer 18F-FDG has homolog properties of glucose, and FDG exhibits greater specificity in assessing aggressive glycolytic cancers. After 18F-FDG enters the cells, 6-P-18F-FDG cannot be further metabolized and stays in the cancer cells, so the uptake of 18F-FDG is proportional to the metabolic rate of glucose. For cancer cells, the up-regulation of transporters on the cancer cell membrane and the increased activity of hexokinase in cancer cells are all associated with the accumulation of 18F-FDG. For rodents, the resolution of PET/CT technology is poor. Micro-PET/CT can be applied to in vivo imaging of small rodents, which can dynamically monitor the distribution changes of 18F-FDG in mice in real-time.

Fig. 1 FDG-6P is trapped within the cancer cellFig. 1 FDG-6P is trapped within the cancer cell (Plöckinger U, et al., 2018)

Our Workflow

  • Wipe down the induction chamber, imaging bed, and thermal pad with ethanol.
  • The mice are placed prone on the imaging bed and the mice are anesthetized.
  • The mice’s tail is heated until the lateral vein is dilated and the needle is inserted.
  • PET scans are performed after 18F-FDG is injected into mice.
  • After the PET scan is done, a CT scan is performed.
  • After the CT scan, the imaging couch is moved to the initial position and the mice are removed from the imaging couch.
  • Data processing.


These assays provide a whole-body metabolism image of tumor-bearing mice, distribution, and metabolism of 18F-FDG in various tissues of mice.


  • Combining nanotechnology with whole-body 18F-FDG-PET/CT technology to develop imaging technology that provides accurate cancer diagnosis, staging, and targeting.
  • Micro-PET/CT imaging can be used in gene therapy to monitor the distribution and expression of gene vectors in vivo.
  • Whole-body 18F-FDG PET/CT and micro-PET/CT imaging can be applied to preclinical drug research to evaluate the changes in the metabolic state of tumor-bearing mice under the action of drugs.
  • Observe whether tumor therapeutic drugs can cross the blood-brain barrier, whether they have organ-specific aggregation, and whether they recognize target receptors.

CD BioGlyco provides whole-body 18F-FDG PET/CT and micro-PET/CT imaging assays of tumor-bearing mice. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.


  1. Plöckinger U, et al. 2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease. Hum Genomics. 2018 Mar 9; 12(1): 14.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.